MIER1 and ovarian cancer: Another is MaxCyte’s drug candidate, MCY-M11, which uses Mesothelin-targeted CAR-M to treat patients with relapsed/refractory ovarian cancer and peritoneal mesothelioma and is currently recruiting volunteers for a phase I clinical trial.238,239 Another study constructed chimeric antigen receptor-macrophage (CAR-M) based on human peritoneal macrophage (PM) gene modification, namely, HF-CAR-PMS expressing HER2-Fc εR1-γ-CAR (HF-CAR).